PRESS RELEASE

NATIONAL RESEARCH AND INNOVATION AGENCY

NO: 015/SP/HM/BKPUK/II/2022

BRIN Facilitates the Initial Phase of Clinical Trials on the Herbal Supplement Products of PT. Biantang Toedjoe

Cooperation in the administration of clinical trials on the herbal supplement products of PT. Bintang Toedjoe is one of efforts made by BRIN to strengthen the research and innovation ecosystem. This activity is also a program in BRIN to facilitate research and innovation to all stakeholders.

Jakarta – BRIN Public Relations. The National Research and Innovation Agency (BRIN) jointly with PT. Bintang Toedjoe collaborates to carry out clinical trials on one of supplement products made from Indonesian native herbs. Site initiation visit as made on Wednesday (16/02) is the initial stage of clinical trial aiming at seeing the effectiveness of using herbal supplements as complementary therapy for patients infected with COVID-19 with mild symptoms.

This herbal supplement is produced by observing the development of the Covid-19 case that has re-emerged in Indonesia. Based on data from the government, the number of confirmed cases was 4.9 million as of 15/2. The deployment speed is much faster than before. Although the symptoms are relatively mild, we must remain vigilant.

Since the Corona virus first appeared in Indonesia, many people have used herbal medicines to keep their immune system. Indonesian native herbs are widely discussed, including red ginger, Sambiloto  (Andrographis paniculata), and other herbal medicines. Red Ginger is believed to be able to boost endurance.

Realizing this, PT Bintang Toedjoe took the initiative to conduct research on COVID-19 patients. This study is intended to examine the effectiveness of using herbal supplements as complementary therapy for patients infected with COVID-19 with mild symptoms.

Head of BRIN, Laksana Tri Handoko supports the efforts of PT. Bintang Toedjoe to make products beneficial to the health based on local wisdom. “The preparation and process of clinical trial collaboration with Bintang Toedjoe has began since the end of 2020 in the midst of the pandemic,” said Handoko.

“This collaboration shows BRIN’s efforts to strengthen local biodiversity-based drug research and its production to become products that meet applicable standards and regulations,” he added.

Acting Deputy for Research and Innovation Utilization, Mego Pinandito said that this clinical trial was conducted to determine the efficacy and safety of herbal supplements. “A randomized, controlled, and double-blind clinical trial is carried out to evaluate the efficacy and safety of administering herbal supplements as adjuvant therapy in standard inpatient treatment of COVID-19 patients with mild symptoms,” said Mego.

According to Mego, collaboration in administering clinical trials is one of efforts to strengthen the research and innovation ecosystem carried out by BRIN. This activity is also one of eight main programs initiated by BRIN to facilitate research and innovation to all stakeholders.

“One of real activities in the strengthening of research and innovation ecosystem is administration of such this clinical trial. Clinical trial is the first item in BRIN’s clinical trial program which will be fully implemented this year,” added Mego.

Mego added that the successful implementation of this clinical trial will certainly need supports from various parties especially PT Bintang Toedjoe, CRO, hospitals, teams of doctors who serve as clinical trial researchers as well as full support from eminent researchers in Indonesia.

President Director of PT Bintang Toedjoe, Fanny Kurniati explained that “Bejo Jahe Merah has been actively involved in maintaining the health of Indonesian people for 10 years. It is hoped that with this clinical trial, Bejo Jahe Merah can contribute more in the fight against the Covid-19 pandemic that occurs in Indonesia and even internationally.”

The Principal Investigator of the Wisma Atlet DC Hospital, Erlang Samoedro said that the implementation of this clinical trial involves COVID-19 patients with mild symptoms at the Kemayoran Athlete Village. “The research will be carried out on COVID-19 patients with mild symptoms starting 18 February 2022 at the Kemayoran Athlete Village Hospital. The research plan has certainly been finalized according to the rules and has received ethical clearance. I hope the research will go well. We need support and prayers from the community.” said Erlang Samoedro.

With this clinical trial, red ginger as an Indonesian native herb is expected to have positive effect on the recovery of COVID-19 patients. Hence, red ginger can be the option for Indonesian families for herbal medicine and will become Indonesia’s pride in the eyes of the world.

Red ginger or Zingiber officinale var. rubrum is a type of red ginger rhizome plant with size smaller than white ginger. Red Ginger has higher content of essential oil than other types of ginger and is often used as the main ingredient for making herbal medicine. Some studies suggest that the content of red ginger is beneficial as an anti-inflammatory and anti-bacterial agent, and can relieve fever.